Literature DB >> 18812217

Poly(I:C) coated PLGA microparticles induce dendritic cell maturation.

Christian Wischke1, Julian Zimmermann, Benjamin Wessinger, Andreas Schendler, Hans-Hubert Borchert, J Hinrich Peters, Thomas Nesselhut, Dirk R Lorenzen.   

Abstract

Microparticles from poly(D,L-lactic-co-glycolic acid) [PLGA] are of steadily rising interest for the delivery of antigens to immune cells and the induction of a long-lasting immune response for vaccination or immunological tumor therapy. However, if the desired vaccine contains only weak antigens and fails to activate the antigen presenting cells (APC), the opposite effect, i.e., the induction of immunotolerance may be observed. Therefore, it was the aim of this study to show the ability of protein loaded PLGA microparticles to additionally carry a specific, surface-coated maturation signal to human dendritic cells (DC), i.e., the most potent APC. Polyinosine-polycytidylic acid [poly(I:C)], a ligand of Toll-like receptor (TLR) 3, was efficiently bound either in a single layer or a multilayer attempt to the surface of diethylaminoethyl dextran modified PLGA microparticles. These particles were effectively phagocytized by DC ex vivo and induced a maturation similar to that achieved with a cytokine cocktail or higher concentrations of soluble poly(I:C). In conclusion, the concept of surface coating of biodegradable microparticles with selected TLR ligands might successfully be used in DC-based cell therapies for cancer or in vaccination trials to induce DC maturation and specifically amplify the immunological response to encapsulated antigens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812217     DOI: 10.1016/j.ijpharm.2008.08.039

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  17 in total

1.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

Review 2.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

3.  Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles.

Authors:  Samar Hamdy; Azita Haddadi; Anooshirvan Shayeganpour; John Samuel; Afsaneh Lavasanifar
Journal:  Pharm Res       Date:  2011-05-11       Impact factor: 4.200

4.  Latent, Immunosuppressive Nature of Poly(lactic-co-glycolic acid) Microparticles.

Authors:  Riley P Allen; Amir Bolandparvaz; Jeffrey A Ma; Vishal A Manickam; Jamal S Lewis
Journal:  ACS Biomater Sci Eng       Date:  2018-02-03

Review 5.  Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.

Authors:  Stacey L Demento; Alyssa L Siefert; Arunima Bandyopadhyay; Fiona A Sharp; Tarek M Fahmy
Journal:  Trends Biotechnol       Date:  2011-04-02       Impact factor: 19.536

6.  Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specific immune responses.

Authors:  Winni De Haes; Stefaan De Koker; Charlotte Pollard; Derek Atkinson; Erika Vlieghe; Jessy Hoste; Joanna Rejman; Stefaan De Smedt; Johan Grooten; Guido Vanham; Ellen Van Gulck
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

Review 7.  Current advances in research and clinical applications of PLGA-based nanotechnology.

Authors:  Jian-Ming Lü; Xinwen Wang; Christian Marin-Muller; Hao Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Expert Rev Mol Diagn       Date:  2009-05       Impact factor: 5.225

8.  Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants.

Authors:  Gloria Jiménez-Sánchez; Vincent Pavot; Christelle Chane-Haong; Nadège Handké; Céline Terrat; Didier Gigmes; Thomas Trimaille; Bernard Verrier
Journal:  Pharm Res       Date:  2014-09-24       Impact factor: 4.200

Review 9.  Protein-based nanoparticles in cancer vaccine development.

Authors:  Medea Neek; Tae Il Kim; Szu-Wen Wang
Journal:  Nanomedicine       Date:  2018-10-04       Impact factor: 5.307

Review 10.  Delivery of host cell-directed therapeutics for intracellular pathogen clearance.

Authors:  Michael A Collier; Matthew D Gallovic; Kevin J Peine; Anthony D Duong; Eric M Bachelder; John S Gunn; Larry S Schlesinger; Kristy M Ainslie
Journal:  Expert Rev Anti Infect Ther       Date:  2013-10-18       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.